< Back to previous page
Organisation
Digestive Oncology
Division
Main organisation:Department of Oncology
Lifecycle:1 Aug 2022 → Today
Organisation profile:
Digestive Oncology
Keywords:oncology
Disciplines:Oncology
Current researchers
1 - 10 of 12 results
- Sabine Tejpar (Responsible)
- Sarah Cappuyns (Member)
- Jeroen Dekervel (Member)
- Frederik Peeters (Member)
- Ting Pu (Member)
- Sabine Tejpar (Member)
- Baki Topal (Member)
- Eric Van Cutsem (Member)
- Fausto Velez Bravo (Member)
- Sara Verbandt (Member)
Projects
1 - 10 of 55
- Querying and exploiting the spatial colorectal tumor ecosystem for novel biological, diagnostic and therapeutic insightsFrom23 Nov 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The evolutionary landscape of colorectal cancer, from polyp to metastasisFrom25 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Multicenter validation trial of [18F]AlF-FAPI-74 for PET imaging of cancer-associated fibroblasts through fibroblast activation protein inhibitors (FAPI) in digestive tumorsFrom1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Optimizing a high throughput TCR-epitope recognition tool to characterize microbiome specific TCR interactions in colorectal cancerFrom1 Oct 2023 → TodayFunding: BOF - doctoral mandates
- Non-genetic drivers of YAP activation in colorectal cancerFrom26 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Study the efficacy and mechanism of targeted TIM3 and VISTA in the treatment of gastroesophageal junction / gastric cancer patients with low immunogenicity and FLOT chemotherapy resistanceFrom14 Feb 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Using mucins as friends in colorectal cancer diagnostics and treatmentFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Infrastructure for Targeted ProteomicsFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Unique IsoPlexis technology for multiplexed single cell functional profilingFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Obesity-associated Hepatocellular Carcinoma at Single Cell Resolution for Risk Prediction and Novel Therapeutics - HepatoSCRIPTFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
Publications
21 - 30 of 1040
- Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib plus cetuximab plus /- binimetinib in BEACON CRC(2021)
Authors: Eric Van Cutsem
Pages: S214 - S214 - MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer(2021)
Authors: Eric Van Cutsem
Pages: S118 - S118 - Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): Outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial(2009)
Authors: Eric Van Cutsem
- Nadunolimab (CAN04), a first-in-class monoclonal antibody against IL1RAP, in combination with chemotherapy in subjects with pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC)(2021)
Authors: Eric Van Cutsem
Pages: S602 - S603 - Bevacizumab as adjuvant treatment for colon cancer: Updated results from the AVANT phase III study by the GERCOR group(2019)
Authors: Eric Van Cutsem
- Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response(2021)
Authors: Eric Van Cutsem
Pages: S203 - S204 - A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status(2009)
Authors: Eric Van Cutsem
Pages: 345 - 345 - Safety and efficacy of bevacizumab (BEV) and chemotherapy in elderly patients with metastatic colorectal cancer (mCRC): results from the BEAT observational cohort study(2009)
Authors: Eric Van Cutsem
Pages: 349 - 349 - Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses(2019)
Authors: Eric Van Cutsem
- MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma: Trial in progress(2021)
Authors: Eric Van Cutsem
Pages: S159 - S159